Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Core Insights - Hoth Therapeutics, Inc. has announced promising findings for its novel therapeutic candidate HT-001, a topical neurokinin 1 receptor (NK1R) antagonist, aimed at treating Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions (EGFRi PPEs) [3][6] Group 1: Clinical Findings - A recent case study highlighted the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer, who experienced full symptom and lesion resolution after one week of treatment, with no recurrence in the following three weeks [2][5] - The patient developed pruritic, burning red papules, a known side effect of EGFR inhibitors, which were effectively treated with HT-001 [2][5] Group 2: Upcoming Presentation - Data regarding HT-001 will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, scheduled for March 7-11, 2025, emphasizing its potential as a breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities [1][4] Group 3: Company Strategy and Research - Hoth Therapeutics is conducting a Phase 2A clinical trial to evaluate the efficacy and safety of HT-001 in a broader patient population, assessing its effectiveness across varying severities of EGFRi PPEs and other dermatologic manifestations induced by EGFR inhibitors [7] - The company aims to address the significant unmet need for long-term, well-tolerated treatment options for cancer patients experiencing debilitating skin reactions [6]